Trial Profile

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics and Efficacy of HMPL-306 in Patients of Relapsed/Refractory Myeloid Leukemia/Neoplasms With IDH1 and/or IDH2 Mutation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranosidenib (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man
Sponsors Hutchison MediPharma; HUTCHMED

13 May 2024 According to a HUTCHMED media release, data from the study to be presented at the EHA Congress in June 2024.
09 Jun 2023 According to a HUTCHMED media release, Based on PD, pharmacokinetic ("PK"), and preliminary clinical findings, a recommended Phase II dose was nominated for the dose expansion phase of the study.
09 Jun 2023 According to a HUTCHMED media release, data from this trial will be presented at the upcoming European Hematology Association ("EHA") Annual Meeting 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com